Literature DB >> 2843576

Gamma-interferon restores listericidal activity and concurrently enhances release of reactive oxygen metabolites in dexamethasone-treated human monocytes.

A Schaffner1, P Rellstab.   

Abstract

By preventing macrophages from destroying phagocytized microorganisms, glucocorticoids lower natural resistance of the host against many pathogens. gamma-Interferon has an opposite effect and restores activity of dexamethasone-treated mononuclear phagocytes against some but not all microorganisms. In the present studies we show that dexamethasone impairs activity of human blood monocytes kept in culture for 36 h against Listeria monocytogenes, without impairing H2O2 or O2- secretion. Likewise dexamethasone does not interfere with activation of systems generating oxygen metabolites by lymphokines. Thus gamma-interferon increases three- to fivefold the capacity of dexamethasone-treated monocytes to secrete O2- or H2O2 upon stimulation by opsonized zymosan, live bacteria, or phorbol myristate acetate. Concurrently gamma-interferon restores listericidal activity of dexamethasone-treated monocytes. After gradual activation by exposure to gamma-interferon for progressive time periods, listericidal activity becomes tightly correlated (r = 0.922-0.994) with the amount of H2O2 or O2- secreted by dexamethasone-treated monocytes. Activation of oxidative systems by the lymphokine is, however, not correlated with the restoration of activity against Aspergillus spores, lost during dexamethasone treatment, which does not depend on antimicrobial oxygen metabolites. Taken together, these observations lend to the hypothesis that glucocorticoids impair nonoxidative defense mechanisms of "resting" macrophages, while gamma-interferon restores macrophage function impaired by glucocorticoids by activating alternate killing systems, which are at least partly of oxidative nature.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843576      PMCID: PMC303602          DOI: 10.1172/JCI113698

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  13 in total

1.  Phagocytic activation of a luminol-dependent chemiluminescence in rabbit alveolar and peritoneal macrophages.

Authors:  R C Allen; L D Loose
Journal:  Biochem Biophys Res Commun       Date:  1976-03-08       Impact factor: 3.575

2.  H2O2 release from human granulocytes during phagocytosis. I. Documentation, quantitation, and some regulating factors.

Authors:  R K Root; J Metcalf; N Oshino; B Chance
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

3.  Killing of Aspergillus spores depends on the anatomical source of the macrophage.

Authors:  A Schaffner; H Douglas; A I Braude; C E Davis
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

4.  Functional identity between murine gamma interferon and macrophage activating factor.

Authors:  R M Schultz; W J Kleinschmidt
Journal:  Nature       Date:  1983 Sep 15-21       Impact factor: 49.962

5.  Dose-dependent effect of glucocorticosteroids on pulmonary defenses in a steroid-resistant host.

Authors:  L L Blackwood; J E Pennington
Journal:  Am Rev Respir Dis       Date:  1982-12

6.  In vitro determination of phagocyte activity by luminol- and lucigenin-amplified chemiluminescence.

Authors:  R Müller-Peddinghaus
Journal:  Int J Immunopharmacol       Date:  1984

7.  Models of T cell deficiency in listeriosis: the effects of cortisone and cyclosporin A on normal and nude BALB/c mice.

Authors:  A Schaffner; H Douglas; C E Davis
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

8.  Hydrogen peroxide metabolism in human monocytes during differentiation in vitro.

Authors:  A Nakagawara; C F Nathan; Z A Cohn
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

9.  Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes.

Authors:  A Schaffner; H Douglas; A Braude
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

10.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Epidemiology of human listeriosis.

Authors:  A Schuchat; B Swaminathan; C V Broome
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

Review 2.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

3.  Effects of an inhaled corticosteroid, budesonide, on alveolar macrophage function in smokers.

Authors:  H Bergstrand; A Björnson; E Blaschke; R Brattsand; A Eklund; K Larsson; M Linden
Journal:  Thorax       Date:  1990-05       Impact factor: 9.139

4.  Adrenaline suppression of the macrophage nitric oxide response to lipopolysaccharide is associated with differential regulation of tumour necrosis factor-alpha and interleukin-10.

Authors:  R B Zinyama; G J Bancroft; L B Sigola
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

5.  Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung.

Authors:  H A Jaffe; R Buhl; A Mastrangeli; K J Holroyd; C Saltini; D Czerski; H S Jaffe; S Kramer; S Sherwin; R G Crystal
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

6.  Enhancement of human monocyte beta-glucan receptors by glucocorticoids.

Authors:  J Kay; J K Czop
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

7.  Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis.

Authors:  T Fehr; G Schoedon; B Odermatt; T Holtschke; M Schneemann; M F Bachmann; T W Mak; I Horak; R M Zinkernagel
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.